BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 2465790)

  • 1. Plasma cell myeloma--new biological insights and advances in therapy.
    Barlogie B; Epstein J; Selvanayagam P; Alexanian R
    Blood; 1989 Mar; 73(4):865-79. PubMed ID: 2465790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features.
    Grogan TM; Durie BG; Lomen C; Spier C; Wirt DP; Nagle R; Wilson GS; Richter L; Vela E; Maxey V
    Blood; 1987 Oct; 70(4):932-42. PubMed ID: 3115338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement.
    Epstein J; Barlogie B; Katzmann J; Alexanian R
    Blood; 1988 Apr; 71(4):861-5. PubMed ID: 2451550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloma phenotype: clues to disease origin and manifestation.
    Epstein J
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):249-56. PubMed ID: 1582972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma.
    Barlogie B; Smallwood L; Smith T; Alexanian R
    Ann Intern Med; 1989 Apr; 110(7):521-5. PubMed ID: 2647015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma.
    Harousseau JL; Shaughnessy J; Richardson P
    Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biology and treatment of multiple myeloma.
    Niesvizky R; Siegel D; Michaeli J
    Blood Rev; 1993 Mar; 7(1):24-33. PubMed ID: 8467229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
    Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
    Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clonogenic precursor cell in multiple myeloma.
    Bakkus MH; Van Riet I; De Greef C; Van Camp B; Thielemans K
    Leuk Lymphoma; 1995 Jul; 18(3-4):221-9. PubMed ID: 8535186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extensive extramedullary disease in myeloma. An uncommon variant with features of poor prognosis and dedifferentiation.
    Sanal SM; Yaylaci M; Mangold KA; Pantazis CG
    Cancer; 1996 Apr; 77(7):1298-302. PubMed ID: 8608506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homing mechanisms in the biology of multiple myeloma.
    Van Camp B; Van Riet I
    Verh K Acad Geneeskd Belg; 1998; 60(3):163-94. PubMed ID: 9803879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells.
    Lee JW; Chung HY; Ehrlich LA; Jelinek DF; Callander NS; Roodman GD; Choi SJ
    Blood; 2004 Mar; 103(6):2308-15. PubMed ID: 14615378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in multiple myeloma.
    Moscinski LC; Ballester OF
    Hematol Oncol; 1994; 12(3):111-23. PubMed ID: 7525447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into role of microenvironment in multiple myeloma.
    Tricot GJ
    Int J Hematol; 2002 Aug; 76 Suppl 1():334-6. PubMed ID: 12430876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.
    Klein B; Zhang XG; Jourdan M; Content J; Houssiau F; Aarden L; Piechaczyk M; Bataille R
    Blood; 1989 Feb; 73(2):517-26. PubMed ID: 2783861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro growth of human multiple myeloma: implications for biology and therapy.
    Caligaris-Cappio F; Gregoretti MG; Ghia P; Bergui L
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):257-71. PubMed ID: 1582973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-kit ligand (SCF) in human multiple myeloma cells.
    Lemoli RM; Fortuna A
    Leuk Lymphoma; 1996 Feb; 20(5-6):457-64. PubMed ID: 8833403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of interleukin-1 by bone marrow myeloma cells.
    Cozzolino F; Torcia M; Aldinucci D; Rubartelli A; Miliani A; Shaw AR; Lansdorp PM; Di Guglielmo R
    Blood; 1989 Jul; 74(1):380-7. PubMed ID: 2665838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.